Oric Pharmaceuticals Inc Cash Flow Conversion Efficiency
Oric Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has a cash flow conversion efficiency ratio of -0.083x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.61 Million) by net assets ($381.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oric Pharmaceuticals Inc (2017–2025)
Cash flow conversion efficiency of Oric Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how Oric Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Oric Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Oric Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Oric Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oric Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see ORIC market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Verve Therapeutics Inc
NASDAQ:VERV
|
-0.059x |
|
PATTIES FOODS
F:PH4
|
N/A |
|
Weibo Corp
NASDAQ:WB
|
0.054x |
|
Jaiprakash Power Ventures Limited
NSE:JPPOWER
|
0.082x |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
0.020x |
|
Acbel Polytech Inc
TW:6282
|
0.013x |
|
China Harzone Industry Corp Ltd
SHE:300527
|
0.010x |
|
Cosmo Pharmaceuticals N.V
F:C43
|
0.013x |
Annual Cash Flow Conversion Efficiency for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Oric Pharmaceuticals Inc from 2017 to 2025. Review how financially flexible is Oric Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $384.36 Million | $-113.37 Million | -0.295x | +36.35% |
| 2024-12-31 | $243.12 Million | $-112.66 Million | -0.463x | -21.19% |
| 2023-12-31 | $224.09 Million | $-85.69 Million | -0.382x | -13.15% |
| 2022-12-31 | $222.35 Million | $-75.14 Million | -0.338x | -54.94% |
| 2021-12-31 | $272.98 Million | $-59.54 Million | -0.218x | -39.62% |
| 2020-12-31 | $289.78 Million | $-45.27 Million | -0.156x | +41.60% |
| 2019-12-31 | $87.97 Million | $-23.53 Million | -0.267x | -183.32% |
| 2018-12-31 | $-64.43 Million | $-20.68 Million | 0.321x | +139.65% |
| 2017-12-31 | $25.73 Million | $-20.83 Million | -0.810x | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more